Cite
HARVARD Citation
Brander, D. et al. (n.d.). Phase II open label study of the oral vascular endothelial growth factor-receptor inhibitor PTK787/ZK222584 (vatalanib) in adult patients with refractory or relapsed diffuse large B-cell lymphoma. Leukemia & lymphoma. 54 (12), pp. 2627-2630. [Online].